Key Performance
More- Earnings Score: N/A
- Momentum Score: 3
- True Yield: N/A
- Financial Health Score: N/A
%20scale(1,1)}%2025%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(1,1)}}%20%23ewMkZ6d8Hun3_ts%20{animation:%20ewMkZ6d8Hun3_ts__ts%204000ms%20linear%20infinite%20normal%20forwards}@keyframes%20ewMkZ6d8Hun3_ts__ts%20{%200%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}%2025%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}}%20]]%3e%3c/style%3e%3cdefs%3e%3clinearGradient%20id='ewMkZ6d8Hun2-fill'%20x1='12.5'%20y1='23.5001'%20x2='-0.868518'%20y2='16.4047'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun2-fill-0'%20offset='0%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun2-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3clinearGradient%20id='ewMkZ6d8Hun3-fill'%20x1='31.5059'%20y1='27.1026'%20x2='10.2884'%20y2='14.9373'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun3-fill-0'%20offset='4.7%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun3-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3c/defs%3e%3cg%20id='ewMkZ6d8Hun2_ts'%20transform='translate(24.943161,19.954806)%20scale(1,1)'%3e%3cpath%20d='M14.8466,29.2814c0,0-14.408088-4.6983-12.05895-19.79995c0,0,1.50345,4.85085,4.13448,5.30845s-2.03592,4.6373,7.92447,14.4915Z'%20transform='translate(-24.943161,-19.954806)'%20fill='url(%23ewMkZ6d8Hun2-fill)'/%3e%3c/g%3e%3cg%20id='ewMkZ6d8Hun3_ts'%20transform='translate(24.9787,20.012362)%20scale(1,1)'%3e%3cpath%20d='M37.4922,21.9282l4.0719.244v-12.81353C31.0713,3.28748,17.7595,7.6502,17.7595,7.6502c.3445-4.51526-3.5707-5.52204-3.5707-5.52204c2.5371,1.52542.3132,6.22373.3132,6.22373C13.0299,0.084092,0,1.02986,0,1.02986C8.92672,4.35528,6.70287,7.98579,6.8908,16.6197c.18794,8.6034,8.3943,12.9966,8.3943,12.9966l-6.60895-.2441v13.2407c0,0,5.48135,2.3797,13.68765,3.1729v-22.3017h-4.4477c-1.0023,0-1.942-.8237-1.942-1.8v-5.7356c0-.9763.9397-1.8,1.942-1.8h4.4477v-1.3424h5.0115v1.3424h5.0115c1.0023,0,1.848.7932,1.848,1.8v5.7356c0,.9763-.8144,1.8-1.848,1.8h-5.0115v22.5153h.2819c11.1192-.0611,15.9428-7.3221,16.256-13.3017.4698-7.7492-6.421-10.7695-6.421-10.7695Z'%20transform='translate(-24.9787,-20.012361)'%20fill='url(%23ewMkZ6d8Hun3-fill)'/%3e%3c/g%3e%3c/svg%3e)
Latest Research & News
Rosen Law Firm is notifying investors about multiple securities class action lawsuits. The primary case involves Soleno Therapeutics, where investors who purchased stock between March 26, 2025 and November 4, 2025 may be entitled to compensation. The lawsuit alleges Soleno made false statements about safety concerns related to its DCCR drug candidate, including fluid retention issues in clinical trials, which posed greater risks than disclosed and reduced commercial viability. The lead plaintiff deadline is May 5, 2026.
04/03/2026, 12:08 PM • GlobeNewswire
A class action lawsuit has been filed against Mereo BioPharma Group plc alleging that the company made materially false and misleading statements regarding its Phase 3 ORBIT and COSMIC clinical programs, which failed to meet their primary endpoints. Investors who purchased Mereo securities between June 5, 2023 and December 26, 2025 are encouraged to join the case, with a lead plaintiff deadline of April 6, 2026.
04/03/2026, 12:00 PM • GlobeNewswire
Pomerantz LLP has filed a class action lawsuit against Mereo BioPharma Group plc alleging securities fraud. The lawsuit stems from Mereo's announcement on December 29, 2025, that its Phase 3 Orbit and Cosmic studies failed to meet primary endpoints, causing the stock to plummet 87.7% to $0.29 per share. Investors have until April 6, 2026, to request Lead Plaintiff status.
03/31/2026, 3:50 PM • GlobeNewswire
Law firm Holzer & Holzer, LLC announced April 6, 2026 lead plaintiff deadlines for shareholder class action lawsuits against BlackRock TCP Capital Corp., Mereo BioPharma Group plc, POMDOCTOR LIMITED, and Ultragenyx Pharmaceutical Inc., alleging materially false statements and/or failure to disclose material facts. Investors who purchased shares during specified periods and suffered losses are encouraged to seek legal representation.
03/24/2026, 8:00 AM • GlobeNewswire
Rosen Law Firm reminds investors in Mereo BioPharma Group plc (NASDAQ: MREO) of the April 6, 2026 lead plaintiff deadline for a securities class action. The lawsuit alleges that Mereo provided misleading statements about Phase 3 clinical trials for setrusumab, expressing confidence in the drug's efficacy while concealing that the trials failed to meet their primary endpoints, causing investors to purchase shares at artificially inflated prices.
03/22/2026, 8:00 AM • GlobeNewswire
A class action lawsuit has been filed against Mereo BioPharma Group plc alleging that the company made materially false and misleading statements to investors regarding its Phase 3 ORBIT and COSMIC clinical programs, which failed to meet their primary endpoints. The lawsuit covers investors who purchased Mereo securities between June 5, 2023 and December 26, 2025, with a lead plaintiff deadline of April 6, 2026.
03/17/2026, 12:00 PM • GlobeNewswire
Law firm Holzer & Holzer reminds investors of April 6, 2026 deadlines to seek lead plaintiff status in shareholder class action lawsuits against BlackRock TCP Capital Corp., Mereo BioPharma Group plc, POMDOCTOR LIMITED, and Ultragenyx Pharmaceutical Inc. The lawsuits allege materially false statements and/or failure to disclose material facts regarding investment valuations, clinical trial results, and fraudulent stock promotion schemes.
03/14/2026, 8:00 AM • GlobeNewswire
Rosen Law Firm is encouraging investors who purchased shares of Mereo BioPharma Group plc (MREO) between June 5, 2023 and December 26, 2025 to join a securities class action lawsuit. The lawsuit alleges that Mereo provided misleading statements about Phase 3 clinical trials for setrusumab, expressing confidence in the drug's success while concealing that the trials failed to meet their primary endpoints, causing investors to purchase shares at artificially inflated prices.
03/13/2026, 4:41 PM • GlobeNewswire
Pomerantz Law Firm has filed class action lawsuits against Mereo BioPharma Group plc, Snowflake Inc., and Navan, Inc. for alleged securities fraud. The primary focus is on Mereo, whose stock plummeted 87.7% after announcing that its Phase 3 clinical trials (Orbit and Cosmic studies) failed to meet primary endpoints in December 2025. Investors who purchased securities during the class period have until April 6, 2026, to join the lawsuit.
03/10/2026, 3:52 PM • GlobeNewswire
Class action lawsuits have been filed against Ultragenyx Pharmaceutical and Mereo BioPharma Group for allegedly misleading investors about Phase III clinical trial results for setrusumab in treating Osteogenesis Imperfecta. Both companies announced on December 29, 2025, that their ORBIT and COSMIC studies failed to meet primary endpoints for reducing annualized fracture rates, resulting in significant stock price declines of 42.32% and 87.7% respectively.
03/08/2026, 7:43 PM • GlobeNewswire
Rosen Law Firm is notifying investors in Mereo BioPharma Group plc who purchased shares between June 5, 2023 and December 26, 2025 of an April 6, 2026 deadline to join a securities class action lawsuit. The lawsuit alleges that Mereo provided misleading statements about Phase 3 clinical trials for setrusumab, expressing confidence in the drug's efficacy while concealing that the trials failed to meet their primary endpoints, causing investors to purchase shares at artificially inflated prices.
03/08/2026, 12:25 AM • GlobeNewswire
A class action lawsuit has been filed against Mereo BioPharma Group plc alleging that the company made materially false and misleading statements regarding its Phase 3 ORBIT and COSMIC clinical programs, which failed to meet their primary endpoints. Investors who purchased Mereo securities between June 5, 2023 and December 26, 2025 are eligible to join the case, with a lead plaintiff deadline of April 6, 2026.
03/06/2026, 12:00 PM • GlobeNewswire
A securities class action lawsuit has been filed against Mereo BioPharma Group plc for allegedly providing misleading statements about Phase 3 clinical trials for setrusumab. The defendants reportedly made positive statements about the drug's potential while concealing that the ORBIT and COSMIC studies failed to meet their primary endpoints, causing investors to purchase shares at artificially inflated prices. The lead plaintiff deadline is April 6, 2026.
03/04/2026, 8:33 PM • GlobeNewswire
Rosen Law Firm has filed securities class action lawsuits against Enphase Energy, Lakeland Industries, and Mereo BioPharma Group on behalf of investors. The primary case detailed involves Enphase Energy, where the firm alleges the company made false statements regarding inventory management, financial prospects, and its ability to mitigate effects from the termination of the Residential Clean Energy Credit. Investors who purchased securities during the specified class periods are encouraged to seek counsel before the April 20, 2026 lead plaintiff deadline.
03/04/2026, 8:03 PM • GlobeNewswire
Robbins LLP has filed a class action lawsuit against Mereo BioPharma Group plc, alleging the company misled investors about Phase 3 ORBIT and COSMIC studies for setrusumab. Both studies failed to meet their primary endpoints for reducing annualized fracture rates, despite the company's prior positive statements. Following the December 29, 2025 announcement, Mereo's stock price plummeted 87.7% from $2.31 to $0.29 per share. Shareholders who purchased ADS between June 5, 2023 and December 26, 2025 may be eligible to participate in the lawsuit.
03/04/2026, 1:40 PM • GlobeNewswire
Peers
Statistics
MoreInformation as of 06/02/2026
Company Profile
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of rare diseases in the United Kingdom and the United States. The company develops Setrusumab, an antibody for the treatment of osteogenesis imperfecta; Alvelestat, an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency associated lung disease; and Vantictumab, an anti-FZD monoclonal antibody for the treatment of autosomal dominant osteopetrosis type 2. It also develops Leflutrozole, an oral aromatase inhibitor, which is in Phase 2 trials for use in the treatment of hypogonadotropic hypogonadism; Navicixizumab, which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Etigilimab, an IgG1 monoclonal antibody which binds to the human TIGIT receptor on immune cells for the Treatment of advanced solid tumors; and Acumapimod, a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; and licensing agreement with AstraZeneca. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, United Kingdom.